PT - JOURNAL ARTICLE AU - Shimizu, Makiko AU - Yano, Hiroshi AU - Nagashima, Satomi AU - Murayama, Norie AU - Zhang, Jun AU - Cashman, John R. AU - Yamazaki, Hiroshi TI - Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on <em>N</em>- and <em>S</em>-Oxygenation Activities AID - 10.1124/dmd.106.013094 DP - 2007 Mar 01 TA - Drug Metabolism and Disposition PG - 328--330 VI - 35 IP - 3 4099 - http://dmd.aspetjournals.org/content/35/3/328.short 4100 - http://dmd.aspetjournals.org/content/35/3/328.full SO - Drug Metab Dispos2007 Mar 01; 35 AB - The decreased capacity of the flavin-containing monooxygenase 3 (FMO3) to oxygenate xenobiotics including trimethylamine is believed to contribute to metabolic disorders. The aim of this study was to functionally characterize FMO3 variants recently found in a Japanese population and compare them with selective functional activity of other FMO3 variants. Recombinant Glu158Lys and Glu158Lys-Glu308Gly FMO3 expressed in Escherichia coli membranes showed slightly decreased N-oxygenation of benzydamine and trimethylamine. Selective functional S-oxygenation of these variants by methyl p-tolyl sulfide or sulindac sulfide was comparable to that of wild-type FMO3. The Glu158Lys-Thr201Lys-Glu308Gly and Val257Met-Met260Val variants showed significantly decreased oxygenation of typical FMO3 substrates (i.e., approximately one-tenth of the Vmax/Km values). Val257Met FMO3 had a lower catalytic efficiency for methyl p-tolyl sulfide and sulindac sulfide S-oxygenation. However, compared with wild-type FMO3, Val257Met FMO3 showed a similar catalytic efficiency for N-oxygenation of benzydamine and trimethylamine. The catalytic efficiency for benzydamine and trimethylamine N-oxygenation by Arg205Cys FMO3 was only moderately decreased, but it possessed decreased sulindac sulfide S-oxygenation activity. Kinetic analysis showed that Arg205Cys FMO3 was inhibited by sulindac in a substrate-dependent manner, presumably because of selective interaction between the variant enzyme and the substrate. The results suggest that the effects of genetic variation of human FMO3 could operate at the functional level for N- and S-oxygenation for typical FMO3 substrates. Genetic polymorphism in the human FMO3 gene might lead to unexpected changes of catalytic efficiency for N- and S-oxygenation of xenobiotics and endogenous materials. The American Society for Pharmacology and Experimental Therapeutics